+1 347 708 0418
Neurological Disorder Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Neurological Disorder Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Segment by Application
Hospital
Clinic
By Company
Novartis
GlaxoSmithKline
Merck & Co.
Bayer
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
1 Study Coverage
1.1 Neurological Disorder Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Neurological Disorder Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Antipsychotic
1.2.3 Hypnotic & Sedative
1.2.4 Analgesics
1.2.5 Anticoagulants
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurological Disorder Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Neurological Disorder Drugs Sales Estimates and Forecasts 2017-2028
2.2 Global Neurological Disorder Drugs Revenue Estimates and Forecasts 2017-2028
2.3 Global Neurological Disorder Drugs Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Neurological Disorder Drugs Sales by Region
2.4.1 Global Neurological Disorder Drugs Sales by Region (2017-2022)
2.4.2 Global Sales Neurological Disorder Drugs by Region (2023-2028)
2.5 Global Neurological Disorder Drugs Revenue by Region
2.5.1 Global Neurological Disorder Drugs Revenue by Region (2017-2022)
2.5.2 Global Neurological Disorder Drugs Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Neurological Disorder Drugs Sales by Manufacturers
3.1.1 Global Top Neurological Disorder Drugs Manufacturers by Sales (2017-2022)
3.1.2 Global Neurological Disorder Drugs Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Neurological Disorder Drugs in 2021
3.2 Global Neurological Disorder Drugs Revenue by Manufacturers
3.2.1 Global Neurological Disorder Drugs Revenue by Manufacturers (2017-2022)
3.2.2 Global Neurological Disorder Drugs Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Neurological Disorder Drugs Revenue in 2021
3.3 Global Neurological Disorder Drugs Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Neurological Disorder Drugs Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Neurological Disorder Drugs Sales by Type
4.1.1 Global Neurological Disorder Drugs Historical Sales by Type (2017-2022)
4.1.2 Global Neurological Disorder Drugs Forecasted Sales by Type (2023-2028)
4.1.3 Global Neurological Disorder Drugs Sales Market Share by Type (2017-2028)
4.2 Global Neurological Disorder Drugs Revenue by Type
4.2.1 Global Neurological Disorder Drugs Historical Revenue by Type (2017-2022)
4.2.2 Global Neurological Disorder Drugs Forecasted Revenue by Type (2023-2028)
4.2.3 Global Neurological Disorder Drugs Revenue Market Share by Type (2017-2028)
4.3 Global Neurological Disorder Drugs Price by Type
4.3.1 Global Neurological Disorder Drugs Price by Type (2017-2022)
4.3.2 Global Neurological Disorder Drugs Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Neurological Disorder Drugs Sales by Application
5.1.1 Global Neurological Disorder Drugs Historical Sales by Application (2017-2022)
5.1.2 Global Neurological Disorder Drugs Forecasted Sales by Application (2023-2028)
5.1.3 Global Neurological Disorder Drugs Sales Market Share by Application (2017-2028)
5.2 Global Neurological Disorder Drugs Revenue by Application
5.2.1 Global Neurological Disorder Drugs Historical Revenue by Application (2017-2022)
5.2.2 Global Neurological Disorder Drugs Forecasted Revenue by Application (2023-2028)
5.2.3 Global Neurological Disorder Drugs Revenue Market Share by Application (2017-2028)
5.3 Global Neurological Disorder Drugs Price by Application
5.3.1 Global Neurological Disorder Drugs Price by Application (2017-2022)
5.3.2 Global Neurological Disorder Drugs Price Forecast by Application (2023-2028)
6 North America
6.1 North America Neurological Disorder Drugs Market Size by Type
6.1.1 North America Neurological Disorder Drugs Sales by Type (2017-2028)
6.1.2 North America Neurological Disorder Drugs Revenue by Type (2017-2028)
6.2 North America Neurological Disorder Drugs Market Size by Application
6.2.1 North America Neurological Disorder Drugs Sales by Application (2017-2028)
6.2.2 North America Neurological Disorder Drugs Revenue by Application (2017-2028)
6.3 North America Neurological Disorder Drugs Market Size by Country
6.3.1 North America Neurological Disorder Drugs Sales by Country (2017-2028)
6.3.2 North America Neurological Disorder Drugs Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Neurological Disorder Drugs Market Size by Type
7.1.1 Europe Neurological Disorder Drugs Sales by Type (2017-2028)
7.1.2 Europe Neurological Disorder Drugs Revenue by Type (2017-2028)
7.2 Europe Neurological Disorder Drugs Market Size by Application
7.2.1 Europe Neurological Disorder Drugs Sales by Application (2017-2028)
7.2.2 Europe Neurological Disorder Drugs Revenue by Application (2017-2028)
7.3 Europe Neurological Disorder Drugs Market Size by Country
7.3.1 Europe Neurological Disorder Drugs Sales by Country (2017-2028)
7.3.2 Europe Neurological Disorder Drugs Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Neurological Disorder Drugs Market Size by Type
8.1.1 Asia Pacific Neurological Disorder Drugs Sales by Type (2017-2028)
8.1.2 Asia Pacific Neurological Disorder Drugs Revenue by Type (2017-2028)
8.2 Asia Pacific Neurological Disorder Drugs Market Size by Application
8.2.1 Asia Pacific Neurological Disorder Drugs Sales by Application (2017-2028)
8.2.2 Asia Pacific Neurological Disorder Drugs Revenue by Application (2017-2028)
8.3 Asia Pacific Neurological Disorder Drugs Market Size by Region
8.3.1 Asia Pacific Neurological Disorder Drugs Sales by Region (2017-2028)
8.3.2 Asia Pacific Neurological Disorder Drugs Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Neurological Disorder Drugs Market Size by Type
9.1.1 Latin America Neurological Disorder Drugs Sales by Type (2017-2028)
9.1.2 Latin America Neurological Disorder Drugs Revenue by Type (2017-2028)
9.2 Latin America Neurological Disorder Drugs Market Size by Application
9.2.1 Latin America Neurological Disorder Drugs Sales by Application (2017-2028)
9.2.2 Latin America Neurological Disorder Drugs Revenue by Application (2017-2028)
9.3 Latin America Neurological Disorder Drugs Market Size by Country
9.3.1 Latin America Neurological Disorder Drugs Sales by Country (2017-2028)
9.3.2 Latin America Neurological Disorder Drugs Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Neurological Disorder Drugs Market Size by Type
10.1.1 Middle East and Africa Neurological Disorder Drugs Sales by Type (2017-2028)
10.1.2 Middle East and Africa Neurological Disorder Drugs Revenue by Type (2017-2028)
10.2 Middle East and Africa Neurological Disorder Drugs Market Size by Application
10.2.1 Middle East and Africa Neurological Disorder Drugs Sales by Application (2017-2028)
10.2.2 Middle East and Africa Neurological Disorder Drugs Revenue by Application (2017-2028)
10.3 Middle East and Africa Neurological Disorder Drugs Market Size by Country
10.3.1 Middle East and Africa Neurological Disorder Drugs Sales by Country (2017-2028)
10.3.2 Middle East and Africa Neurological Disorder Drugs Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Novartis
11.1.1 Novartis Corporation Information
11.1.2 Novartis Overview
11.1.3 Novartis Neurological Disorder Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Novartis Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novartis Recent Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Corporation Information
11.2.2 GlaxoSmithKline Overview
11.2.3 GlaxoSmithKline Neurological Disorder Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 GlaxoSmithKline Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 GlaxoSmithKline Recent Developments
11.3 Merck & Co.
11.3.1 Merck & Co. Corporation Information
11.3.2 Merck & Co. Overview
11.3.3 Merck & Co. Neurological Disorder Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Merck & Co. Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Merck & Co. Recent Developments
11.4 Bayer
11.4.1 Bayer Corporation Information
11.4.2 Bayer Overview
11.4.3 Bayer Neurological Disorder Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Bayer Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Bayer Recent Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Corporation Information
11.5.2 AstraZeneca Overview
11.5.3 AstraZeneca Neurological Disorder Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 AstraZeneca Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 AstraZeneca Recent Developments
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Corporation Information
11.6.2 Boehringer Ingelheim Overview
11.6.3 Boehringer Ingelheim Neurological Disorder Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Boehringer Ingelheim Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Boehringer Ingelheim Recent Developments
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Corporation Information
11.7.2 Teva Pharmaceutical Overview
11.7.3 Teva Pharmaceutical Neurological Disorder Drugs Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Teva Pharmaceutical Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Teva Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Neurological Disorder Drugs Industry Chain Analysis
12.2 Neurological Disorder Drugs Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Neurological Disorder Drugs Production Mode & Process
12.4 Neurological Disorder Drugs Sales and Marketing
12.4.1 Neurological Disorder Drugs Sales Channels
12.4.2 Neurological Disorder Drugs Distributors
12.5 Neurological Disorder Drugs Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Neurological Disorder Drugs Industry Trends
13.2 Neurological Disorder Drugs Market Drivers
13.3 Neurological Disorder Drugs Market Challenges
13.4 Neurological Disorder Drugs Market Restraints
14 Key Findings in The Global Neurological Disorder Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Neurological Disorder Drugs Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Antipsychotic
Table 3. Major Manufacturers of Hypnotic & Sedative
Table 4. Major Manufacturers of Analgesics
Table 5. Major Manufacturers of Anticoagulants
Table 6. Major Manufacturers of Others
Table 7. Global Neurological Disorder Drugs Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 8. Global Neurological Disorder Drugs Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 9. Global Neurological Disorder Drugs Sales by Region (2017-2022) & (K Units)
Table 10. Global Neurological Disorder Drugs Sales Market Share by Region (2017-2022)
Table 11. Global Neurological Disorder Drugs Sales by Region (2023-2028) & (K Units)
Table 12. Global Neurological Disorder Drugs Sales Market Share by Region (2023-2028)
Table 13. Global Neurological Disorder Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 14. Global Neurological Disorder Drugs Revenue Market Share by Region (2017-2022)
Table 15. Global Neurological Disorder Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 16. Global Neurological Disorder Drugs Revenue Market Share by Region (2023-2028)
Table 17. Global Neurological Disorder Drugs Sales by Manufacturers (2017-2022) & (K Units)
Table 18. Global Neurological Disorder Drugs Sales Share by Manufacturers (2017-2022)
Table 19. Global Neurological Disorder Drugs Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 20. Global Neurological Disorder Drugs Revenue Share by Manufacturers (2017-2022)
Table 21. Neurological Disorder Drugs Price by Manufacturers (2017-2022) &(USD/Unit)
Table 22. Global Neurological Disorder Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Neurological Disorder Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neurological Disorder Drugs as of 2021)
Table 24. Neurological Disorder Drugs Manufacturing Base Distribution and Headquarters
Table 25. Manufacturers Neurological Disorder Drugs Product Offered
Table 26. Date of Manufacturers Enter into Neurological Disorder Drugs Market
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Neurological Disorder Drugs Sales by Type (2017-2022) & (K Units)
Table 29. Global Neurological Disorder Drugs Sales by Type (2023-2028) & (K Units)
Table 30. Global Neurological Disorder Drugs Sales Share by Type (2017-2022)
Table 31. Global Neurological Disorder Drugs Sales Share by Type (2023-2028)
Table 32. Global Neurological Disorder Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 33. Global Neurological Disorder Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 34. Global Neurological Disorder Drugs Revenue Share by Type (2017-2022)
Table 35. Global Neurological Disorder Drugs Revenue Share by Type (2023-2028)
Table 36. Neurological Disorder Drugs Price by Type (2017-2022) & (USD/Unit)
Table 37. Global Neurological Disorder Drugs Price Forecast by Type (2023-2028) & (USD/Unit)
Table 38. Global Neurological Disorder Drugs Sales by Application (2017-2022) & (K Units)
Table 39. Global Neurological Disorder Drugs Sales by Application (2023-2028) & (K Units)
Table 40. Global Neurological Disorder Drugs Sales Share by Application (2017-2022)
Table 41. Global Neurological Disorder Drugs Sales Share by Application (2023-2028)
Table 42. Global Neurological Disorder Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 43. Global Neurological Disorder Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 44. Global Neurological Disorder Drugs Revenue Share by Application (2017-2022)
Table 45. Global Neurological Disorder Drugs Revenue Share by Application (2023-2028)
Table 46. Neurological Disorder Drugs Price by Application (2017-2022) & (USD/Unit)
Table 47. Global Neurological Disorder Drugs Price Forecast by Application (2023-2028) & (USD/Unit)
Table 48. North America Neurological Disorder Drugs Sales by Type (2017-2022) & (K Units)
Table 49. North America Neurological Disorder Drugs Sales by Type (2023-2028) & (K Units)
Table 50. North America Neurological Disorder Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 51. North America Neurological Disorder Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 52. North America Neurological Disorder Drugs Sales by Application (2017-2022) & (K Units)
Table 53. North America Neurological Disorder Drugs Sales by Application (2023-2028) & (K Units)
Table 54. North America Neurological Disorder Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 55. North America Neurological Disorder Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 56. North America Neurological Disorder Drugs Sales by Country (2017-2022) & (K Units)
Table 57. North America Neurological Disorder Drugs Sales by Country (2023-2028) & (K Units)
Table 58. North America Neurological Disorder Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 59. North America Neurological Disorder Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 60. Europe Neurological Disorder Drugs Sales by Type (2017-2022) & (K Units)
Table 61. Europe Neurological Disorder Drugs Sales by Type (2023-2028) & (K Units)
Table 62. Europe Neurological Disorder Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 63. Europe Neurological Disorder Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 64. Europe Neurological Disorder Drugs Sales by Application (2017-2022) & (K Units)
Table 65. Europe Neurological Disorder Drugs Sales by Application (2023-2028) & (K Units)
Table 66. Europe Neurological Disorder Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 67. Europe Neurological Disorder Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 68. Europe Neurological Disorder Drugs Sales by Country (2017-2022) & (K Units)
Table 69. Europe Neurological Disorder Drugs Sales by Country (2023-2028) & (K Units)
Table 70. Europe Neurological Disorder Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 71. Europe Neurological Disorder Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 72. Asia Pacific Neurological Disorder Drugs Sales by Type (2017-2022) & (K Units)
Table 73. Asia Pacific Neurological Disorder Drugs Sales by Type (2023-2028) & (K Units)
Table 74. Asia Pacific Neurological Disorder Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 75. Asia Pacific Neurological Disorder Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 76. Asia Pacific Neurological Disorder Drugs Sales by Application (2017-2022) & (K Units)
Table 77. Asia Pacific Neurological Disorder Drugs Sales by Application (2023-2028) & (K Units)
Table 78. Asia Pacific Neurological Disorder Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 79. Asia Pacific Neurological Disorder Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 80. Asia Pacific Neurological Disorder Drugs Sales by Region (2017-2022) & (K Units)
Table 81. Asia Pacific Neurological Disorder Drugs Sales by Region (2023-2028) & (K Units)
Table 82. Asia Pacific Neurological Disorder Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 83. Asia Pacific Neurological Disorder Drugs Revenue by Region (2023-2028) & (US$ Million)
Table 84. Latin America Neurological Disorder Drugs Sales by Type (2017-2022) & (K Units)
Table 85. Latin America Neurological Disorder Drugs Sales by Type (2023-2028) & (K Units)
Table 86. Latin America Neurological Disorder Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 87. Latin America Neurological Disorder Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 88. Latin America Neurological Disorder Drugs Sales by Application (2017-2022) & (K Units)
Table 89. Latin America Neurological Disorder Drugs Sales by Application (2023-2028) & (K Units)
Table 90. Latin America Neurological Disorder Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 91. Latin America Neurological Disorder Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 92. Latin America Neurological Disorder Drugs Sales by Country (2017-2022) & (K Units)
Table 93. Latin America Neurological Disorder Drugs Sales by Country (2023-2028) & (K Units)
Table 94. Latin America Neurological Disorder Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 95. Latin America Neurological Disorder Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 96. Middle East and Africa Neurological Disorder Drugs Sales by Type (2017-2022) & (K Units)
Table 97. Middle East and Africa Neurological Disorder Drugs Sales by Type (2023-2028) & (K Units)
Table 98. Middle East and Africa Neurological Disorder Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 99. Middle East and Africa Neurological Disorder Drugs Revenue by Type (2023-2028) & (US$ Million)
Table 100. Middle East and Africa Neurological Disorder Drugs Sales by Application (2017-2022) & (K Units)
Table 101. Middle East and Africa Neurological Disorder Drugs Sales by Application (2023-2028) & (K Units)
Table 102. Middle East and Africa Neurological Disorder Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 103. Middle East and Africa Neurological Disorder Drugs Revenue by Application (2023-2028) & (US$ Million)
Table 104. Middle East and Africa Neurological Disorder Drugs Sales by Country (2017-2022) & (K Units)
Table 105. Middle East and Africa Neurological Disorder Drugs Sales by Country (2023-2028) & (K Units)
Table 106. Middle East and Africa Neurological Disorder Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 107. Middle East and Africa Neurological Disorder Drugs Revenue by Country (2023-2028) & (US$ Million)
Table 108. Novartis Corporation Information
Table 109. Novartis Description and Major Businesses
Table 110. Novartis Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 111. Novartis Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 112. Novartis Recent Developments
Table 113. GlaxoSmithKline Corporation Information
Table 114. GlaxoSmithKline Description and Major Businesses
Table 115. GlaxoSmithKline Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 116. GlaxoSmithKline Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. GlaxoSmithKline Recent Developments
Table 118. Merck & Co. Corporation Information
Table 119. Merck & Co. Description and Major Businesses
Table 120. Merck & Co. Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 121. Merck & Co. Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Merck & Co. Recent Developments
Table 123. Bayer Corporation Information
Table 124. Bayer Description and Major Businesses
Table 125. Bayer Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 126. Bayer Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. Bayer Recent Developments
Table 128. AstraZeneca Corporation Information
Table 129. AstraZeneca Description and Major Businesses
Table 130. AstraZeneca Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 131. AstraZeneca Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. AstraZeneca Recent Developments
Table 133. Boehringer Ingelheim Corporation Information
Table 134. Boehringer Ingelheim Description and Major Businesses
Table 135. Boehringer Ingelheim Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 136. Boehringer Ingelheim Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. Boehringer Ingelheim Recent Developments
Table 138. Teva Pharmaceutical Corporation Information
Table 139. Teva Pharmaceutical Description and Major Businesses
Table 140. Teva Pharmaceutical Neurological Disorder Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
Table 141. Teva Pharmaceutical Neurological Disorder Drugs Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Teva Pharmaceutical Recent Developments
Table 143. Key Raw Materials Lists
Table 144. Raw Materials Key Suppliers Lists
Table 145. Neurological Disorder Drugs Distributors List
Table 146. Neurological Disorder Drugs Customers List
Table 147. Neurological Disorder Drugs Market Trends
Table 148. Neurological Disorder Drugs Market Drivers
Table 149. Neurological Disorder Drugs Market Challenges
Table 150. Neurological Disorder Drugs Market Restraints
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
List of Figures
Figure 1. Neurological Disorder Drugs Product Picture
Figure 3. Global Neurological Disorder Drugs Market Share by Type in 2021 & 2028
Figure 3. Antipsychotic Product Picture
Figure 4. Hypnotic & Sedative Product Picture
Figure 5. Analgesics Product Picture
Figure 6. Anticoagulants Product Picture
Figure 7. Others Product Picture
Figure 8. Global Neurological Disorder Drugs Market Share by Application in 2021 & 2028
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Neurological Disorder Drugs Report Years Considered
Figure 12. Global Neurological Disorder Drugs Sales 2017-2028 (K Units)
Figure 13. Global Neurological Disorder Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Neurological Disorder Drugs Revenue 2017-2028 (US$ Million)
Figure 15. Global Neurological Disorder Drugs Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 16. Global Neurological Disorder Drugs Sales Market Share by Region (2017-2022)
Figure 17. Global Neurological Disorder Drugs Sales Market Share by Region (2023-2028)
Figure 18. North America Neurological Disorder Drugs Sales YoY (2017-2028) & (K Units)
Figure 19. North America Neurological Disorder Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 20. Europe Neurological Disorder Drugs Sales YoY (2017-2028) & (K Units)
Figure 21. Europe Neurological Disorder Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 22. Asia-Pacific Neurological Disorder Drugs Sales YoY (2017-2028) & (K Units)
Figure 23. Asia-Pacific Neurological Disorder Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 24. Latin America Neurological Disorder Drugs Sales YoY (2017-2028) & (K Units)
Figure 25. Latin America Neurological Disorder Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 26. Middle East & Africa Neurological Disorder Drugs Sales YoY (2017-2028) & (K Units)
Figure 27. Middle East & Africa Neurological Disorder Drugs Revenue YoY (2017-2028) & (US$ Million)
Figure 28. The Neurological Disorder Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 29. The Top 5 and 10 Largest Manufacturers of Neurological Disorder Drugs in the World: Market Share by Neurological Disorder Drugs Revenue in 2021
Figure 30. Global Neurological Disorder Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 31. Global Neurological Disorder Drugs Sales Market Share by Type (2017-2028)
Figure 32. Global Neurological Disorder Drugs Revenue Market Share by Type (2017-2028)
Figure 33. Global Neurological Disorder Drugs Sales Market Share by Application (2017-2028)
Figure 34. Global Neurological Disorder Drugs Revenue Market Share by Application (2017-2028)
Figure 35. North America Neurological Disorder Drugs Sales Market Share by Type (2017-2028)
Figure 36. North America Neurological Disorder Drugs Revenue Market Share by Type (2017-2028)
Figure 37. North America Neurological Disorder Drugs Sales Market Share by Application (2017-2028)
Figure 38. North America Neurological Disorder Drugs Revenue Market Share by Application (2017-2028)
Figure 39. North America Neurological Disorder Drugs Sales Share by Country (2017-2028)
Figure 40. North America Neurological Disorder Drugs Revenue Share by Country (2017-2028)
Figure 41. U.S. Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 42. Canada Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 43. Europe Neurological Disorder Drugs Sales Market Share by Type (2017-2028)
Figure 44. Europe Neurological Disorder Drugs Revenue Market Share by Type (2017-2028)
Figure 45. Europe Neurological Disorder Drugs Sales Market Share by Application (2017-2028)
Figure 46. Europe Neurological Disorder Drugs Revenue Market Share by Application (2017-2028)
Figure 47. Europe Neurological Disorder Drugs Sales Share by Country (2017-2028)
Figure 48. Europe Neurological Disorder Drugs Revenue Share by Country (2017-2028)
Figure 49. Germany Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 50. France Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 51. U.K. Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 52. Italy Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 53. Russia Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 54. Asia Pacific Neurological Disorder Drugs Sales Market Share by Type (2017-2028)
Figure 55. Asia Pacific Neurological Disorder Drugs Revenue Market Share by Type (2017-2028)
Figure 56. Asia Pacific Neurological Disorder Drugs Sales Market Share by Application (2017-2028)
Figure 57. Asia Pacific Neurological Disorder Drugs Revenue Market Share by Application (2017-2028)
Figure 58. Asia Pacific Neurological Disorder Drugs Sales Share by Region (2017-2028)
Figure 59. Asia Pacific Neurological Disorder Drugs Revenue Share by Region (2017-2028)
Figure 60. China Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 61. Japan Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 62. South Korea Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 63. India Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 64. Australia Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 65. Taiwan Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 66. Indonesia Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 67. Thailand Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 68. Malaysia Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 69. Philippines Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 70. Latin America Neurological Disorder Drugs Sales Market Share by Type (2017-2028)
Figure 71. Latin America Neurological Disorder Drugs Revenue Market Share by Type (2017-2028)
Figure 72. Latin America Neurological Disorder Drugs Sales Market Share by Application (2017-2028)
Figure 73. Latin America Neurological Disorder Drugs Revenue Market Share by Application (2017-2028)
Figure 74. Latin America Neurological Disorder Drugs Sales Share by Country (2017-2028)
Figure 75. Latin America Neurological Disorder Drugs Revenue Share by Country (2017-2028)
Figure 76. Mexico Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 77. Brazil Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 78. Argentina Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 79. Middle East and Africa Neurological Disorder Drugs Sales Market Share by Type (2017-2028)
Figure 80. Middle East and Africa Neurological Disorder Drugs Revenue Market Share by Type (2017-2028)
Figure 81. Middle East and Africa Neurological Disorder Drugs Sales Market Share by Application (2017-2028)
Figure 82. Middle East and Africa Neurological Disorder Drugs Revenue Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Neurological Disorder Drugs Sales Share by Country (2017-2028)
Figure 84. Middle East and Africa Neurological Disorder Drugs Revenue Share by Country (2017-2028)
Figure 85. Turkey Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 86. Saudi Arabia Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 87. U.A.E Neurological Disorder Drugs Revenue (2017-2028) & (US$ Million)
Figure 88. Neurological Disorder Drugs Value Chain
Figure 89. Neurological Disorder Drugs Production Process
Figure 90. Channels of Distribution
Figure 91. Distributors Profiles
Figure 92. Bottom-up and Top-down Approaches for This Report
Figure 93. Data Triangulation
Figure 94. Key Executives Interviewed
Buy
